Last reviewed · How we verify
NH102
At a glance
| Generic name | NH102 |
|---|---|
| Also known as | H04 |
| Sponsor | Jiangsu Nhwa Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Multiple Ascending Dose Study of NH102 in Healthy Subjects (PHASE1)
- A Phase II Study to Evaluate NH102 for Depression (PHASE2)
- Single Ascending Dose Study of NH102 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NH102 CI brief — competitive landscape report
- NH102 updates RSS · CI watch RSS
- Jiangsu Nhwa Pharmaceutical Co., Ltd. portfolio CI